Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) EBIT: 2016-2024

Historic EBIT for Summit Therapeutics (SMMT) over the last 3 years, with Dec 2024 value amounting to -$65.6 million.

  • Summit Therapeutics' EBIT fell 81.20% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$180.7 million, marking a year-over-year decrease of 92.35%. This contributed to the annual value of -$226.0 million for FY2024, which is 62.93% up from last year.
  • Latest data reveals that Summit Therapeutics reported EBIT of -$65.6 million as of Q4 2024, which was down 12.40% from -$58.4 million recorded in Q3 2024.
  • Summit Therapeutics' EBIT's 5-year high stood at -$7.6 million during Q1 2020, with a 5-year trough of -$65.6 million in Q4 2024.
  • For the 3-year period, Summit Therapeutics' EBIT averaged around -$36.3 million, with its median value being -$28.4 million (2023).
  • Per our database at Business Quant, Summit Therapeutics' EBIT climbed by 4.49% in 2020 and then crashed by 184.88% in 2024.
  • Over the past 4 years, Summit Therapeutics' EBIT (Quarterly) stood at -$7.6 million in 2020, then reached -$20.3 million in 2022, then plummeted by 78.38% to -$36.2 million in 2023, then crashed by 81.20% to -$65.6 million in 2024.
  • Its last three reported values are -$65.6 million in Q4 2024, -$58.4 million for Q3 2024, and -$36.2 million during Q4 2023.